Morphomolecular motifs of pulmonary neoangiogenesis in interstitial lung diseases

European Respiratory Journal

Volumn 55, Issue 3, 2020, Pages

  Ackermann, Maximilian ^a,b   Stark, Helge ^c   Neubert, Lavinia ^c,d   Schubert, Stephanie ^c   Borchert, Paul ^c   Linz, Friedemann ^a   Wagner, Willi L ^e,f   Stiller, Wolfram ^e,f   Wielpütz, Mark ^e,f   Hoefer, Anne ^c   Haverich, Axel ^c,d   Mentzer, Steven J ^g   Shah, Harshit R ^c,d   Welte, Tobias ^c,d   Kuehnel, Mark ^c,d   Jonigk, Danny ^c,d  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH)   (Germany)

^e Heidelberg Translational Lung Research Center (TLRC)   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 2; COLLAGEN TYPE 3; COLLAGEN TYPE 4; CYTOKERATIN 7; GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE 14; PLATELET ENDOTHELIAL CELL ADHESION MOLECULE 1; PODOPLANIN; SOMATOMEDIN C;

ADULT; ALVEOLAR FIBROELASTOSIS; ANGIOGENESIS; ARTICLE; CLINICAL ARTICLE; COL1A1 GENE; CONTROLLED STUDY; CORROSION CASTING; DENSITY; DOWN REGULATION; FEMALE; GENE; GENE EXPRESSION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IGF1 GENE; IMMUNOHISTOCHEMISTRY; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; MALE; MEG3 GENE; MICRO-COMPUTED TOMOGRAPHY; MORPHOMETRY; NEOANGIOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; THY1 GENE; UPREGULATION; USUAL INTERSITIAL PNEUMONIA; VOLUMETRY;

EID: 85081944485     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00933-2019     Document Type: Article

References (46)

1. Selman M, Pardo A. The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2003; 29: 3 Suppl, S93–S97.
2. Tonnesen MG, Feng X, Clark RA. Angiogenesis in wound healing. J Investig Dermatol Symp Proc 2000; 5: 40–46.
3. Crapo JD, Barry BE, Gehr P, et al. Cell number and cell characteristics of the normal human lung. Am Rev Respir Dis 1982; 126: 332–337.
4. Gehr P, Bachofen M, Weibel ER. The normal human lung: ultrastructure and morphometric estimation of diffusion capacity. Respir Physiol 1978; 32: 121–140.
5. Ebina M, Shimizukawa M, Shibata N, et al. Heterogeneous increase in CD34-positive alveolar capillaries in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2004; 169: 1203–1208.
6. Konerding MA, Gibney BC, Houdek JP, et al. Spatial dependence of alveolar angiogenesis in post-pneumonectomy lung growth. Angiogenesis 2012; 15: 23–32.
7. Tammela T, Zarkada G, Wallgard E, et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008; 454: 656–660.
8. Hlushchuk R, Riesterer O, Baum O, et al. Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation. Am J Pathol 2008; 173: 1173–1185. Epub 2008 Sep 11.
9. Ackermann M, Konerding MA. Vascular casting for the study of vascular morphogenesis. Methods Mol Biol 2015; 1214: 49–66.
10. Tzouvelekis A, Anevlavis S, Bouros D. Angiogenesis in interstitial lung diseases: a pathogenetic hallmark or a bystander? Respir Res 2006; 7: 82.
11. Parra ER, David YR, da Costa LR, et al. Heterogeneous remodeling of lung vessels in idiopathic pulmonary fibrosis. Lung 2005; 183: 291–300.
12. Hanumegowda C, Farkas L, Kolb M. Angiogenesis in pulmonary fibrosis: too much or not enough? Chest 2012; 142: 200–207.
13. Burdick MD, Murray LA, Keane MP, et al. CXCL11 attenuates bleomycin-induced pulmonary fibrosis via inhibition of vascular remodeling. Am J Respir Crit Care Med 2005; 171: 261–268.
14. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082.
15. Rivera-Ortega P, Hayton C, Blaikley J, et al. Nintedanib in the management of idiopathic pulmonary fibrosis: clinical trial evidence and real-world experience. Ther Adv Respir Dis 2018; 12: 1753466618800618,
16. Ackermann M, Kim YO, Wagner WL, et al. Effects of nintedanib on the microvascular architecture in a lung fibrosis model. Angiogenesis 2017; 20: 359–372.
17. Ask K, Tandon K, Ayaub E, et al. Nintedanib prevents IL-6-mediated secretion of CCL-18 in alternatively activated macrophages and transition of fibroblasts to myofibroblasts. Eur Respir J 2017; 50: PA3478. .
18. Tandon K, Herrmann F, Ayaub E, et al. Nintedanib attenuates the polarization of profibrotic macrophages through the inhibition of tyrosine phosphorylation on CSF1 receptor. Am J Respir Crit Care Med 2017; 195: A2397.
19. Jacob J, Bartholmai BJ, Rajagopalan S, et al. Mortality prediction in idiopathic pulmonary fibrosis: evaluation of computer-based CT analysis with conventional severity measures. Eur Respir J 2017; 49: 1601011.
20. Puxeddu E, Cavalli F, Pezzuto G, et al. Impact of pulmonary vascular volume on mortality in IPF: is it time to reconsider the role of vasculature in disease pathogenesis and progression? Eur Respir J 2017; 49: 1602345.
21. Hashimoto N, Phan SH, Imaizumi K, et al. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2010; 43: 161–172.
22. Jonigk D, Stark H, Braubach P, et al. Morphological and molecular motifs of fibrosing pulmonary injury patterns. J Pathol Clin Res 2019; 5: 256–271.
23. du Bois R, King TE Jr. Challenges in pulmonary fibrosis · 5: the NSIP/UIP debate. Thorax 2007; 62: 1008–1012.
24. Vandesompele J, De Preter K, Pattyn F, et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: RESEARCH0034.
25. Farkas L, Gauldie J, Voelkel NF, et al. Pulmonary hypertension and idiopathic pulmonary fibrosis: a tale of angiogenesis, apoptosis, and growth factors. Am J Respir Cell Mol Biol 2011; 45: 1–15.
26. Mentzer SJ, Konerding MA. Intussusceptive angiogenesis: expansion and remodeling of microvascular networks. Angiogenesis 2014; 17: 499–509.
27. Konerding MA, Turhan A, Ravnic DJ, et al. Inflammation-induced intussusceptive angiogenesis in murine colitis. Anat Rec 2010; 293: 849–857.
28. + progenitor to endothelial cell transition in post-pneumonectomy angiogenesis. Am J Respir Cell Mol Biol 2012; 46: 283–289.
29. + accessory cells during murine lung regeneration. Stem Cell Res 2013; 10: 267–277.
30. Renzoni EA, Walsh DA, Salmon M, et al. Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med 2003; 167: 438–443.
31. Ackermann M, Houdek JP, Gibney BC, et al. Sprouting and intussusceptive angiogenesis in postpneumonectomy lung growth: mechanisms of alveolar neovascularization. Angiogenesis 2014; 17: 541–551.
32. Jonigk D, Rath B, Borchert P, et al. Comparative analysis of morphological and molecular motifs in bronchiolitis obliterans and alveolar fibroelastosis after lung and stem cell transplantation. J Pathol Clin Res 2016; 3: 17–28.
33. von der Thüsen JH, Hansell DM, Tominaga M, et al. Pleuroparenchymal fibroelastosis in patients with pulmonary disease secondary to bone marrow transplantation. Mod Pathol 2011; 24: 1633–1639.
34. Jacobo SM, Kazlauskas A. Insulin-like growth factor 1 (IGF-1) stabilizes nascent blood vessels. J Biol Chem 2015; 290: 6349–6360.
35. Ackermann M, Morse BA, Delventhal V, et al. Anti-VEGFR2 and anti-IGF-1R-adnectins inhibit Ewing’s sarcoma A673-xenograft growth and normalize tumor vascular architecture. Angiogenesis 2012; 15: 685–695.
36. Xi Y, Kim T, Brumwell AN, et al. Local lung hypoxia determines epithelial fate decisions during alveolar regeneration. Nat Cell Biol 2017; 19: 904–914.
37. Varone F, Sgalla G, Iovene B, et al. Nintedanib for the treatment of idiopathic pulmonary fibrosis. Expert Opin Pharmacother 2018; 19: 167–175.
38. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58–62.
39. Farkas L, Farkas D, Ask K, et al. VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J Clin Invest 2009; 119: 1298–1311.
40. Colombat M, Mal H, Groussard O, et al. Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis: histopathologic study on lung explant specimens and correlations with pulmonary hemodynamics. Hum Pathol 2007; 38: 60–65.
41. Neubert L, Borchert P, Shin HO, et al. Comprehensive three-dimensional morphology of neoangiogenesis in pulmonary veno-occlusive disease and pulmonary capillary hemangiomatosis. J Pathol Clin Res 2019; 5: 108–114.
42. Ackermann M, Gaumann A, Mentzer SJ, et al. Plexiform vasculopathy in chronic thromboembolic pulmonary hypertension. Am J Respir Crit Care Med 2017; 196: e48–e51.
43. Wnuk M, Hlushchuk R, Tuffin G, et al. The effects of PTK787/ZK222584, an inhibitor of VEGFR and PDGFRβ pathways, on intussusceptive angiogenesis and glomerular recovery from Thy1.1 nephritis. Am J Pathol 2011; 178: 1899–1912. .
44. Alvarez DF, Huang L, King JA, et al. Lung microvascular endothelium is enriched with progenitor cells that exhibit vasculogenic capacity. Am J Physiol Lung Cell Mol Physiol 2008; 294: L419–L430.
45. Misharin AV, Morales-Nebreda L, Reyfman PA, et al. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span. J Exp Med 2017; 214: 2387–2404.
46. Dimova I, Karthik S, Makanya A, et al. SDF-1/CXCR4 signalling is involved in blood vessel growth and remodelling by intussusception. J Cell Mol Med 2019; 23: 3916–3926.